Ragini R. Kudchadkar

Also affiliated with Daiichi-Sankyo (South Korea), Daiichi Sankyo (United States)

Biochemistry, Genetics and Molecular BiologyMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma”.

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002478

N/A

4.0DataRank · unranked

140 citations

Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl +24 more

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Neuro-Oncology(2021)10.1093/neuonc/noab094

N/A

4.0DataRank · unranked

126 citations

Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid +18 more

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

New England Journal of Medicine(2018)10.1056/nejmoa1805453

N/A

1.1DataRank · unranked

1335 citations

Peter A. Forsyth, Alain Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos +17 more

Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition

Frontiers in Oncology(2022)10.3389/fonc.2022.836845

N/A

0DataRank · unranked

7 citations

Michael B. Ware, Aditya Rali, Susanne L. Linderman, Jessica G. Shantha, David H. Lawson +6 more

FcγRIIB expressed on CD8+T cells limits responsiveness to PD-1 checkpoint inhibition in cancer

Science Translational Medicine(2023)10.1126/scitranslmed.add1868

N/A

0DataRank · unranked

21 citations

Marvi Tariq, Megan M. Wyatt, Charlotte Duneton, Kirsten Baecher, Chrystal M. Paulos +4 more

Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

(2023)10.1158/2159-8290.c.6549583.v1

N/A

0DataRank · unranked

0 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

FcγRIIB is a T cell checkpoint in antitumor immunity

JCI Insight(2021)10.1172/jci.insight.135623

N/A

0DataRank · unranked

31 citations

Anna B. Morris, Marvi Tariq, Kelsey B. Bennion, Sayalee Potdar, Ragini R. Kudchadkar +3 more

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Cancer Discovery(2021)10.1158/2159-8290.cd-21-1141

N/A

0DataRank · unranked

102 citations

Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp +26 more

Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx

Blood Advances(2020)10.1182/bloodadvances.2019001148

N/A

0DataRank · unranked

9 citations

Manila Gaddh, Abhinav Hoskote, Michael Brown, Virginia Merrill, Sean R. Stowell +7 more